NI201000091A - Inhibidores de cinesina como productos terapéuticos para el cáncer. - Google Patents

Inhibidores de cinesina como productos terapéuticos para el cáncer.

Info

Publication number
NI201000091A
NI201000091A NI201000091A NI201000091A NI201000091A NI 201000091 A NI201000091 A NI 201000091A NI 201000091 A NI201000091 A NI 201000091A NI 201000091 A NI201000091 A NI 201000091A NI 201000091 A NI201000091 A NI 201000091A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
compounds
cancers
ksp
novel
Prior art date
Application number
NI201000091A
Other languages
English (en)
Inventor
Abrams Tinya
Barsanti Paul
Duhl David
Faure Michel
A Renhowe Paul
Olga Walter Annette
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI201000091A publication Critical patent/NI201000091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona novedosos compuestos de imidazol que inhiben la actividad de la proteína de huso de cinesina (KSP, también denominada como Eg5). Los inhibidores de KSP pueden reducir la proliferación celular indeseada, y proporcionan otros efectos terapéuticos. La invención también proporciona composiciones farmacéuticas que contienen estos compuestos novedosos, y métodos para utilizar los inhibidores de KSP novedosos y sus composiciones farmacéuticas para tratar diferentes tipos de cánceres. Los compuestos, composiciones y métodos de la invención son en especial útiles para el tratamiento de ciertas clases de cánceres que son resistentes a los tratamientos con fármacos convencionales, debido a que se muestra que estos cánceres siguen siendo sensibles a los compuestos de la invención.
NI201000091A 2007-12-14 2010-06-02 Inhibidores de cinesina como productos terapéuticos para el cáncer. NI201000091A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
NI201000091A true NI201000091A (es) 2011-03-15

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000091A NI201000091A (es) 2007-12-14 2010-06-02 Inhibidores de cinesina como productos terapéuticos para el cáncer.

Country Status (30)

Country Link
US (2) US8252832B2 (es)
EP (1) EP2229170B1 (es)
JP (1) JP5501976B2 (es)
KR (1) KR20100098394A (es)
CN (1) CN101939005B (es)
AR (1) AR069676A1 (es)
AU (1) AU2008337570B2 (es)
BR (1) BRPI0821248A2 (es)
CA (1) CA2708822A1 (es)
CL (1) CL2008003707A1 (es)
CO (1) CO6290651A2 (es)
CR (1) CR11412A (es)
DO (1) DOP2010000175A (es)
EA (1) EA018014B1 (es)
EC (1) ECSP10010248A (es)
ES (1) ES2459442T3 (es)
GE (1) GEP20125647B (es)
GT (1) GT201000172A (es)
IL (1) IL205831A0 (es)
MA (1) MA31872B1 (es)
MY (1) MY150214A (es)
NI (1) NI201000091A (es)
NZ (1) NZ585142A (es)
PA (1) PA8807801A1 (es)
PE (1) PE20091451A1 (es)
SM (1) SMP201000095B (es)
TN (1) TN2010000204A1 (es)
TW (1) TW200930704A (es)
UY (1) UY31532A1 (es)
WO (1) WO2009077448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
BR112017027813A2 (pt) * 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
AU2017380871A1 (en) 2016-12-21 2019-07-11 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
JP2010515687A (ja) 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体

Also Published As

Publication number Publication date
SMAP201000095A (it) 2010-09-10
AU2008337570A1 (en) 2009-06-25
US8252832B2 (en) 2012-08-28
CN101939005A (zh) 2011-01-05
CO6290651A2 (es) 2011-06-20
US20130012560A1 (en) 2013-01-10
PE20091451A1 (es) 2009-10-19
AR069676A1 (es) 2010-02-10
SMP201000095B (it) 2011-09-09
US20090239922A1 (en) 2009-09-24
GT201000172A (es) 2012-04-30
TW200930704A (en) 2009-07-16
US8664256B2 (en) 2014-03-04
IL205831A0 (en) 2010-11-30
DOP2010000175A (es) 2010-06-30
BRPI0821248A2 (pt) 2015-06-16
ES2459442T3 (es) 2014-05-09
CL2008003707A1 (es) 2009-06-05
CR11412A (es) 2010-06-30
UY31532A1 (es) 2009-08-03
ECSP10010248A (es) 2010-07-30
PA8807801A1 (es) 2009-07-23
EA201000900A1 (ru) 2011-02-28
GEP20125647B (en) 2012-09-25
JP5501976B2 (ja) 2014-05-28
TN2010000204A1 (en) 2011-11-11
EA018014B1 (ru) 2013-04-30
WO2009077448A1 (en) 2009-06-25
MA31872B1 (fr) 2010-11-01
MY150214A (en) 2013-12-13
EP2229170B1 (en) 2014-01-22
AU2008337570B2 (en) 2012-04-05
EP2229170A1 (en) 2010-09-22
JP2011506402A (ja) 2011-03-03
KR20100098394A (ko) 2010-09-06
CA2708822A1 (en) 2009-06-25
NZ585142A (en) 2012-03-30
CN101939005B (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
NI201000091A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer.
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
DOP2003000614A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
ECSP109965A (es) Imidazoles fusionados para el tratamiento del cancer
DOP2022000082A (es) Heterociclos bicíclicos como inhibidores de fgfr
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CU23784B7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
DOP2011000110A (es) “derivados de bencimidazol n3 alquilados como inhibidores de mek”
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP088706A (es) Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cáncer de próstata
ECSP099539A (es) Derivados de 3-cinolinacarboxamida y su uso para tratar el cáncer
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
PH12017501881A1 (en) Methods for treating cancer
CU20100121A7 (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2023000837A1 (es) Derivados de tetrazol como inhibidores de trpa1
CL2023000838A1 (es) Derivados de tetrazol como inhibidores de trpa1
DOP2009000143A (es) Quinazolinas para la inhibicion de pdk1
CU20100029A7 (es) Imidazoles fusionados para el tratamiento del cáncer